Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The highly conserved Wnt signalling pathway plays an important role in embryonic development and disease pathogenesis, most notably cancer. The ‘canonical’ or β‐catenin‐dependent Wnt signal initiates at the cell plasma membrane with the binding of Wnt proteins to Frizzled:LRP5/LRP6 receptor complexes and is mediated by the translocation of the transcription co‐activator protein, β‐catenin, into the nucleus. β‐Catenin then forms a complex with T‐cell factor (TCF)/lymphoid enhancer binding factor (LEF) transcription factors to regulate multiple gene programmes. These programmes play roles in cell proliferation, migration, vasculogenesis, survival and metabolism. Mutations in Wnt signalling pathway components lead to constitutively active Wnt signalling that drives aberrant expression of these programmes and development of cancer. It has been a longstanding and challenging goal to develop therapies that can interfere with the TCF/LEF–β‐catenin transcriptional complex. This review will focus on the (i) structural considerations for targeting the TCF/LEF–β‐catenin and co‐regulatory complexes in the nucleus, (ii) current molecules that directly target TCF/LEF–β‐catenin activity and (iii) ideas for targeting newly discovered components of the TCF/LEF–β‐catenin complex and/or downstream gene programmes regulated by these complexes. Linked Articles: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 2×
“…on inhibitors of cyclin-dependent kinases (CDK) CDK4 and CDK6, rather than directly targeting CCND1, has been successful and led to two FDA-approved drugs (palbociclib and ribociclib) for patients with advanced breast cancer (Finn et al., 2015, 2016; Turner et al., 2015; Hortobagyi et al., 2016).”
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“This process has been successfully targeted leading to the development of multiple anti-angiogenesis agents that are FDA approved and widely used in the clinic (Goel et al., 2012; Jain, 2014).”
BackgroundCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 1×
“However, Wnt target genes that drive proliferation such as CMYC and CCND1 are often viewed as un-druggable since they lack enzymatic activity that can be inhibited and because they are required in non-malignant cells (Musgrove et al., 2011; Rennoll and Yochum, 2015; Koh et al., 2016).”
BackgroundPolakis, P. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008052 · Cited by 847 · cited 1×
“These advances are encouraging and suggest that the pace of drug development for Wntlinked cancers is accelerating (Kahn, 2014; Zhan et al., 2016; Nusse and Clevers, 2017).”
BackgroundWnt Signaling and an APC-Related Gene Specify Endoderm in Early C. elegans Embryos
Rocheleau, C. E., Downs, W. D., Lin, R., Wittmann, C., Bei, Y., Cha, Y.-H., Ali, M., Priess, J. R., & Mello, C. C. (1997) · Cell · doi:10.1016/s0092-8674(00)80531-0 · Cited by 660
Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer
Pate, K. T., Stringari, C., Sprowl‐Tanio, S., Wang, K., TeSlaa, T., Hoverter, N. P., McQuade, M. M., Garner, C., Digman, M. A., Teitell, M. A., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201488598 · Cited by 459
Self-citationVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Gonsalves, F. C., Klein, K., Carson, B. B., Katz, S., Ekas, L. A., Evans, S., Nagourney, R., Cardozo, T., Brown, A. M. C., & DasGupta, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017496108 · Cited by 337
Mitotic and mitogenic Wnt signalling
Niehrs, C., & Acebron, S. P. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.124 · Cited by 305 · cited 2×
“The main mediator of this cell surface-to-nucleus signal is β-catenin, a membrane/cytoplasmic armadillo repeat protein with no ability to promote transcription by binding DNA on its own (Niehrs and Acebron, 2012;Masuda and Ishitani, 2017; Nusse and Clevers, 2017).”
BackgroundFang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190
Cited by
Stem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02872 · Cited by 285
The WNT signaling pathways in wound healing and fibrosis
Burgy, O., & Königshoff, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.017 · Cited by 175
Wang, H., Deng, G., Ai, M., Xu, Z., Mou, T., Yu, J., Liu, H., Wang, S., & Li, G. (2019) · Oncogene · doi:10.1038/s41388-018-0532-5 · Cited by 117
Metadata
- Authors
- Lyou, Y., Habowski, A. N., Chen, G. T., & Waterman, M. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-08-24
- Volume
- 174
- Issue
- 24
- Pages
- 4589-4599
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2741047383
- Cited by
- 58
- References
- 15
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.